|
Anemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Repercussion of myeloid cell phenotype specific to BM after burn injury could plausibly account for a defective late stage RBC maturation resulting in anemia of critical illness.
|
31824951 |
2019 |
|
Anemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BACKGROUNDAlthough it is considered that the pathogenesis of diabetic retinopathy (DR) in type 2 diabetes mellitus (T2DM) is primarily due to chronic hyperglycemia resulting in vascular changes and retinal ischemia, the red blood cells (RBCs) disorders might also represent an important pathophysiological risk factor.OBJECTIVETo evaluate whether the RBC properties contribute to DR development and progression in T2DM.METHODSThis prospective observational study comprised 247 persons with T2DM free of DR or with non proliferative DR without any signs of anaemia.
|
30103306 |
2019 |
|
Anemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the effectiveness of anemia management and audit with feedback practices in reducing overuse of RBC transfusion.
|
30357323 |
2019 |
|
Anemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twenty percent of cases showed evidence of acute coronary ischemia that was first detected during transfusion with rising troponins or electrocardiographic abnormalities, all in association with RBC transfusion for anemia.
|
30488953 |
2019 |
|
Anemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
ESAs (including biosimilars) may be offered to patients with chemotherapy-associated anemia whose cancer treatment is not curative in intent and whose hemoglobin has declined to < 10 g/dL.RBC transfusion is also an option.
|
30971397 |
2019 |
|
Anemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
ESAs (including biosimilars) may be offered to patients with chemotherapy-associated anemia whose cancer treatment is not curative in intent and whose hemoglobin has declined to < 10 g/dL.RBC transfusion is also an option.
|
30969847 |
2019 |
|
Anemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
For the PS negative sub-fraction of RBCs, the size of the RBC was as expected but the average hemoglobin, Hb, content was below the threshold which defines anemia.
|
30617361 |
2019 |
|
Anemia, Sickle Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
Modulation of the AC/cAMP/PKA pathway could have the potential to be an effective therapeutic approach for SCD through shear-induced improvements of RBC deformability.
|
31306111 |
2019 |
|
Anemia, Sickle Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we explored five patients with SCD and multiple RBC alloantibodies who received various forms of immunosuppressive therapy in an attempt to prevent or treat severe DHTRs.
|
30848512 |
2019 |
|
Anemia, Sickle Cell
|
0.100 |
Biomarker
|
disease |
BEFREE |
Forty percent of institutions (33% of non-SCTCs) employ RBC genotyping to evaluate the red cell phenotype for SCD patients.
|
30740798 |
2019 |
|
Anemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using a structured literature review and grading process, the Transfusion and Anemia Expertise Initiative panel concluded that there is currently insufficient evidence to recommend specific RBC transfusion variables in children requiring extracorporeal membrane oxygenation, ventricular assist device, or renal replacement therapy support.
|
30161071 |
2018 |
|
Anemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Transfusion and Anemia Expertise Initiative Consensus Conference developed pediatric specific recommendations regarding RBC transfusion management in the critically ill child with acute bleeding, as well as recommendations to help guide future research priorities.
|
30161067 |
2018 |
|
Anemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fifty-eight infants (15 after pediatric surgery and 43 after cardiac surgery) with anemia requiring RBC transfusion were included.
|
29406374 |
2018 |
|
Anemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transfusion and Anemia Expertise Initiative developed pediatric-specific good practice statements and recommendations regarding RBC transfusion management in the general PICU population, as well as recommendations to guide future research priorities.
|
30161064 |
2018 |
|
Anemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pathologists' most relevant recommendation: "Do not transfuse more units of blood than absolutely necessary"; highest priority: "Do not transfuse more than the minimum number of RBC units necessary to relieve symptoms of anemia or to return a patient to a safe hemoglobin range (7-8 g/dL in stable, noncardiac inpatients)."
|
29425260 |
2018 |
|
Anemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Transfusion and Anemia Expertise Initiative Consensus Conference developed specific recommendations regarding RBC transfusion management in critically ill children with respiratory failure, as well as recommendations to guide future research.
|
30161065 |
2018 |
|
Anemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Low-dose thalidomide and prednisone alone or combined are effective therapies in some persons with primary myelofibrosis (PMF) and anemia with or with RBC transfusion dependence.
|
29335406 |
2018 |
|
Anemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transfusion and Anemia Expertise Initiative Consensus Conference experts developed and voted on a total of four clinical and four research recommendations focused on RBC transfusion in the critically ill child with nonhemorrhagic shock.
|
30161066 |
2018 |
|
Anemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Transfusion and Anemia Expertise Initiative recommendations on RBC transfusions are based on clinical evidence and aim to limit unnecessary and potentially harmful transfusions.
|
30161073 |
2018 |
|
Anemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
RBC clearance through loss of complement regulatory proteins (CRPs) is a significant contributor to anemia in Plasmodium falciparum infection, but its role in Plasmodium vivax infection is unknown.
|
30429373 |
2018 |
|
Anemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
RBC-EV levels correlated with patient hematocrit, reflecting degree of anemia.
|
30214417 |
2018 |
|
Anemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients with sickle cell disease, Transfusion and Anemia Expertise Initiative recommends: 1) RBC transfusion to achieve a target hemoglobin concentration of 10 g/dL rather than hemoglobin of less than 30% prior to surgical procedures requiring general anesthesia and 2) exchange transfusion over simple (nonexchange) transfusion if the child's condition is deteriorating (based on clinical judgment), otherwise a simple, nonexchange RBC transfusion is recommended.
|
30161070 |
2018 |
|
Anemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transfusion and Anemia Expertise Initiative Consensus Conference experts developed and agreed upon two clinical and two research recommendations focused on RBC transfusion in the critically ill child with acute brain injury.
|
30161068 |
2018 |
|
Anemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Transfusion and Anemia Expertise Initiative recommendations provide important clinical guidance and applicable tools to avoid unnecessary RBC transfusions.
|
30180125 |
2018 |
|
Anemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Transfusion and Anemia Expertise Initiative consensus conference developed recommendations for selection and processing of RBC units for critically ill children.
|
30161072 |
2018 |